"
Team:Stanford-Brown/HumanPractices/PatentEthics
From 2012.igem.org
Vishesh.jain (Talk | contribs) |
(→Patent Ethics) |
||
| Line 15: | Line 15: | ||
== '''Patent Ethics''' == | == '''Patent Ethics''' == | ||
| - | + | In addition to the Synbio Community’s practical need for a guide to help navigate patent law, we also felt it would be invaluable to invigorate the discussion surrounding the ethics of gene patents. Thus we crafted a gene patent ethics review to complement our more practical guide. This review includes two documents, a full paper on the topic as well as an “at a glance” document for those who want to start thinking about these issues in a less rigorous fashion. | |
| + | |||
| + | As an introduction, it has been estimated that approximately 20% of the human genome is patented . While this is a generalized statement, most would find this notion, at least in part, unsettling. As synthetic biology is a relatively new field with unprecedented possibilities, indubitably, there is a great debate surrounding gene patenting in moral, practical, and legal domains. | ||
| + | |||
| + | The two documents below seek to elucidate the variety of dilemmas that the synbio-patent interaction has provoked and to hopefully offer some objective commentary and insight for the iGEM and greater synthetic biology community. | ||
Revision as of 17:59, 3 October 2012
Patent Ethics
In addition to the Synbio Community’s practical need for a guide to help navigate patent law, we also felt it would be invaluable to invigorate the discussion surrounding the ethics of gene patents. Thus we crafted a gene patent ethics review to complement our more practical guide. This review includes two documents, a full paper on the topic as well as an “at a glance” document for those who want to start thinking about these issues in a less rigorous fashion.
As an introduction, it has been estimated that approximately 20% of the human genome is patented . While this is a generalized statement, most would find this notion, at least in part, unsettling. As synthetic biology is a relatively new field with unprecedented possibilities, indubitably, there is a great debate surrounding gene patenting in moral, practical, and legal domains.
The two documents below seek to elucidate the variety of dilemmas that the synbio-patent interaction has provoked and to hopefully offer some objective commentary and insight for the iGEM and greater synthetic biology community.
